ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1466	National Cancer Institute	Html	en	Penile Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of penile cancer.	penile shaft 0.625965 lower prevalence 0.447004 disease stage 0.456978 odds ratio 0.446539 infected primary lesion 0.547017 PDQ cancer information 0.772684 poorly differentiated tumors 0.538507 clinical trials 0.807326 observational studies 0.567664 cancer information summary 0.707707 breast cancer prevention 0.552706 bilateral inguinal lymph 0.695554 penile HPV 0.678754 NCI’s PDQ 0.530402 PDQ Adult Treatment 0.603184 NCI PDQ cancer 0.668979 stage IV cancer 0.495897 lymph nodes 0.744697 regional inguinal lymph 0.679281 human papillomavirus 0.609539 positive lymph nodes 0.642063 penile cancer. 0.820523 single case 0.4576 antibiotic therapy 0.431816 node metastasis 0.456545	United States 0.583912 new drugs 0.43228 decreased risk 0.457358 microscopic node metastases 0.575056 node dissection 0.478206 prophylactic lymphadenectomy 0.435367 penile cancer 0.96059 National Cancer Institute 0.555757 distant metastases 0.467783 PDQ documents 0.502265 case series studies 0.559492 precursor lesions progress 0.546799 local control 0.438046 Bowen disease 0.435373 inguinal lymph node 0.850704 adjunctive inguinal dissection 0.622563 male newborn circumcision 0.57819 invasive penile cancer. 0.789576 case reports 0.439988 surgical techniques 0.438147 bilateral ilioinguinal dissection 0.579916 confidence interval 0.450369 Inguinal adenopathy 0.494134 human papillomavirus DNA 0.562566	CLICK HERE
1489	National Cancer Institute	Html	en	Salivary Gland Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of salivary gland cancer.	salivary gland carcinoma 0.511905 salivary duct carcinoma 0.495372 salivary neoplasms 0.436633 salivary gland neoplasms 0.699057 salivary gland tumors 0.679256 Oral Surg Oral 0.463588 Oral Med Oral 0.447637 Med Oral Pathol 0.44551 Labial salivary gland 0.469995 malignant salivary gland 0.526645 salivary gland neoplasm 0.484554 acinic cell carcinoma 0.43649 Salivary Gland Disease 0.467146 minor salivary glands 0.598035 epithelial salivary gland 0.497367 minor salivary glands. 0.45198 Gnepp DR 0.473942 Auclair PL 0.442506 salivary gland tissue 0.459874 Ellis GL 0.451621 salivary gland 0.899362 mesenchymal salivary gland 0.475624 mucoepidermoid carcinoma 0.443769 intraoral minor salivary 0.423491	Salivary gland tumours 0.500385 salivary gland lesion 0.478189 intraoral salivary glands 0.465746 parotid gland 0.430561 adenoid cystic carcinoma 0.455777 PUBMED Abstract 0.424085 major salivary glands 0.755909 salivary gland neoplasms. 0.489141 salivary gland register 0.455761 minor salivary gland 0.596497 common salivary gland 0.491012 Central salivary gland 0.46762 salivary gland accessions 0.477176 cell carcinoma 0.493942 salivary gland regions 0.454552 salivary gland sites 0.489141 Abstract 0.471491 salivary glands. 0.452306 salivary glands 0.905936 Surg Oral Med 0.463412 salivary gland tumor 0.497715 major salivary gland 0.545945 major salivary glands. 0.437313 salivary gland origin 0.593941	CLICK HERE
1570	National Cancer Institute	Html	en	Neuroblastoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood neuroblastoma.	cancer treatment 0.566372 neuroblastoma 0.915175 tumor biology 0.626071 malignant tumor cells 0.558857 body 0.647664 chemotherapy 0.49696 PDQ cancer information 0.548139 clinical trials 0.793699 cancer information summary 0.51948 low-risk neuroblastoma 0.514243 clinical trial 0.659456 high-risk neuroblastoma 0.659347 tumor histology 0.510739 favorable tumor biology 0.542334 unfavorable tumor biology 0.522724 treatment clinical trial 0.493293 lymph nodes 0.501542 radiation therapy 0.646669 Treatment Editorial Board 0.49305 neuroblastoma spreads 0.512002 Neuroblastoma Treatment 0.537187 neuroblastoma cell 0.510315 treatment 0.836037 time neuroblastoma 0.52866 cancer cells 0.648207	recurrent neuroblastoma 0.571181 neuroblastoma talk 0.50906 Neuroendocrine tumor cells 0.542579 neuroblastoma cells 0.566453 treatment clinical trials 0.520878 National Cancer Institute 0.53108 tumor cells 0.633055 intermediate-risk neuroblastoma 0.542626 new treatment 0.533829 Progressive/Recurrent Neuroblastoma 0.502026 primary tumor 0.499207 metastatic tumor 0.511477 blood 0.501083 Iodine 131-MIBG therapy 0.54351 bone marrow 0.53977 stage 4S neuroblastoma 0.523743 cancer clinical trials 0.49476 Recurrent CNS Neuroblastoma 0.519837 stem cell rescue 0.505173 tumor 0.835165 treatment options 0.506317 cancer 0.929691 standard treatment 0.535537 metastatic neuroblastoma 0.513574	CLICK HERE
1925	National Cancer Institute	Html	es	Tratamiento del cáncer de hipofaringe (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de hipofaringe.	Neck Cancer 0.247768 siguientes procedimientos 0.753135 siguientes aspectos 0.304732 rayos x 0.282557 pequeñas marcas 0.25053 estadio ivc 0.310167 enlace drugs approved 0.28833 estadio iva 0.312892 vías respiratorias 0.282072 National Cancer Institute 0.233317 siguientes opciones 0.237415 siguientes riesgos 0.225706	realidad células 0.310814 cuerpo.ampliar radioterapia 0.360468 Instituto Nacional 0.267315 hormonas tiroideas 0.252232 malla ayuda 0.248727 PDQ Tratamiento 0.272276 paciente fuma 0.301748 Physician Data Query 0.341971 estadio i 0.315197 ganglio linfático mide 0.903903 glándula tiroidea 0.554743 siguientes estadios 0.417752	CLICK HERE
2079	National Cancer Institute	Html	es	BRCA1 y BRCA2: Riesgo de cáncer y pruebas genéticas	Hoja informativa acerca de los genes BRCA1 y BRCA2, de qué hacer si una persona tiene resultados positivos para una de estas alteraciones, y de las consecuencias de las pruebas genéticas.	with inherited mutations 0.40971 Fanconi anemia 0.442696 general padecerán cáncer 0.476912 Lubinski J 0.414965 Cancer Statistics Review 0.41308 brca1 or brca2 0.539593 largo plazo 0.414755 American Cancer Society 0.413258 posibles perjuicios 0.41059 Biallelic mutations 0.410182 National Comprehensive Cancer 0.413868 Breast Cancer Research 0.418728 with brca1 or 0.423664 Múltiples cánceres 0.410805 mutaciones específicas dañinas 0.471623 brca2 mutations 0.589927 among male brca1 0.421616 or genetic predisposition 0.416124 BRCA2 padecerán 0.44228 gen palb2 0.413362 BRCA1 mutation carriers 0.444383 Estados Unidos 0.427518 padecerán cáncer 0.566332 mutaciones dañinas 0.851633 PubMed Abstract 0.989166	mutation carriers identified 0.410419 seno masculino 0.429589 Clinical Oncology 0.441136 BRCA2 carriers 0.419799 risks among brca1 0.420776 BRCA2 mutation carriers 0.508942 BRCA2 mutations detected 0.422577 contralateral breast 0.413156 National Cancer Institute 0.442375 Cancer Research 0.430441 Breast Cancer Prevention 0.417323 antecedentes familiares 0.783866 or brca2 mutations 0.503006 mutation carriers with 0.423928 breast cancer 0.531052 clinical breast examination 0.410267 mujeres padecerán 0.409393 mujeres portadoras 0.421608 gen brca1 0.536899 asesoría genética 0.435987 cancer risk 0.445775 New England Journal 0.415366 bilateral profiláctica 0.437879 BRCA2 mutations account 0.4223	CLICK HERE
2964	National Cancer Institute	Html	en	E-Cigarettes	If you’re thinking about using an e-cig, here are three things you should know.	hookah water pipe 0.494728 large premium cigars 0.459683 oral tobacco 0.537822 greater risks 0.403027 cancer-causing substances 0.387897 chemical additives 0.392918 burning cigarette 0.414008 throat cancer 0.383899 lung cancer 0.382731 tobacco 0.978071 supportive friends 0.453267 cancer-causing chemicals 0.389232 hookah smoke 0.446625 Cigar smoke 0.40643 greater health issues 0.438887 carbon monoxide 0.384792 cigar tobacco 0.526627 paper wrapping 0.393371 leaf tobacco 0.522574 tobacco products 0.765605 harm brain development 0.443591 high risk 0.381422 little filtered cigars 0.462027 older siblings 0.385847 Hookah tobacco 0.577414	healthy way 0.432788 Nicotine exposure 0.405523 toxic chemicals 0.388306 harmless water vapor 0.448644 potentially harmful chemicals 0.482948 high levels 0.460808 health consequences 0.391113 cigarette smoke 0.424559 cigarette smoking 0.578732 heart disease 0.388527 DipfreeTXT program 0.386418 vape pens 0.380351 hookah smoking 0.490187 multiple tobacco products 0.584428 spitting tobacco 0.542435 mouth cancer 0.379991 size—from smaller cigars 0.460695 cigarette tobacco 0.544703 Cigar users 0.389386 quitSTART app 0.388192 e-cigarettes 0.388072 smokeless tobacco 0.780551 risks 0.529273 health risks 0.470569	CLICK HERE
15634	National Cancer Institute	Html	en	Step 3: Peer Review and Funding Outcomes	The NCI review process seeks to achieve a balanced grant portfolio, that addresses scientific priorities. Learn about NCI’s peer review for grant applications.	Final funding decisions 0.68801 conservative funding range 0.692235 Funding Opportunity Announcement 0.669325 grant applications 0.543909 grant review cycle 0.655483 previously reviewed submissions 0.591298 scientific research community 0.67817 grants management specialist 0.65539 JIT requirements 0.569359 NCI budget 0.675257 specific grant application 0.663769 funding guidelines 0.594989 Grants Policy Manual 0.654435 grants management 0.718868 Resubmission Applications 0.561239 additional information 0.630031 funding mechanisms 0.587684 future funding 0.591477 preliminary funding allocations 0.74522 JIT Procedures 0.570833 program allocations 0.582504 program priorities 0.540659 NCI division 0.672087 grants management staff 0.632016 JIT information 0.763408	review percentile/impact score 0.647883 NIH Policy 0.59572 responsible NIH official 0.747181 Peer Review process 0.887529 NCI Scientific Program 0.984221 NCI Peer Review 0.873194 important scientific priorities 0.646164 nih peer review 0.942228 Program Leadership Committee 0.639488 subsequent new application 0.637696 unsuccessful initial submission 0.60519 scientific program staff 0.658004 Scientific Review 0.61867 promising scientific opportunities 0.644998 administrative review 0.543867 following JIT information 0.687226 NCI grants process 0.840796 unsuccessful initial application 0.638737 scientific merit 0.540216 Scientific Program Leadership 0.821474 funding decisions 0.80612 dual review process 0.70096 timely review 0.580483 Public Health Service 0.644114	CLICK HERE
16716	National Cancer Institute	Html	en	NCI Cancer Moonshot℠ Public Access and Data Sharing Policy	NCI has established a data sharing policy that supports open, public access to all research and data for projects funded as part of the Cancer Moonshot. Find details on the policy.	Underlying Primary Data 0.835591 National Cancer Advisory 0.204571 Creative Commons 0.266314 Cancer Moonshotâ„  0.229846 Moonshot Research Project 0.326921 public domain tool 0.238273 extramural Cancer Moonshot 0.217832 Cancer Moonshot beginning 0.210573 cancer research 0.226051 Data Sharing Repositories 0.219342 underlying data 0.223365 NIH Sharing Policies 0.206938 Genomic Data Sharing 0.238331 Moonshot Research Projects 0.712789 Cancer Moonshotâ„  Research 0.221203 NIH Data Sharing 0.283755 National Cancer Institute 0.205263 Cancer Moonshot Projects 0.211704 public access 0.827988	Blue Ribbon Panel 0.23172 Cancer Moonshot Research 0.963477 independent data access 0.222133 data sharing policies 0.240205 Public Access Policy. 0.214656 nih public access 0.329101 Genomic Data Commons 0.208284 Enhanced Data Sharing 0.250631 Public Access Policy 0.237717 NCI-Supported Cancer Moonshot 0.379658 appropriate Public Access 0.254192 cancer research projects 0.217712 NCI researchers 0.205129 NCI intramural Cancer 0.231006 Data Sharing Policy 0.330676 Rule.7 Underlying Primary 0.217644 Data Sharing Plan 0.965755 intramural Cancer Moonshot 0.258314 Cancer Moonshot Public 0.244424	CLICK HERE
16848	National Cancer Institute	Html	en	Treatment and Therapy	Nanotechnology offers the means to target therapies directly and selectively to cancerous cells and neoplasms. With these tools, clinicians can safely and effectively deliver chemotherapy, radiotherapy, and the next generation of immuno- and gene therapies to the tumor. Futhermore, surgical resection of tumors can be guided and enhanced by way of nanotechnology tools. Find out how nanotechnology will offer the next generation of our therapeutic arsenal to the patient.	cancer treatment 0.854097 tumor type 0.82492 tumor tissues 0.889211 Cancer therapies 0.820703 large surface area 0.827043 nanoparticles 0.943843 superficial tumor 0.871555 nanotechnology cancer therapy 0.925806 multiple myeloma patients 0.821624 RNA-based genetic therapeutics 0.82576 cancer therapeutics 0.879587 vivo RNA nanoparticle 0.839578 nucleic acids 0.851966 electromagnetic radiation modalities 0.829021 cancer immunotherapy deepens 0.869884 artificial antigen 0.824529 Host Cell Response 0.906892 radiation therapy 0.999924 Standalone nanoparticle vaccines 0.835115 multiple dendritic cell 0.822099 conventional radiation therapy 0.856977 tumor vasculature permeability 0.888964 Cancer Nanotechnology Excellence 0.870289 tumor mass 0.82439	photodynamic therapy 0.836532 Cancer Nanotechnology awardees 0.958295 cancer cells 0.999243 external radiation sources 0.839028 small molecule compounds 0.820814 Cancer Therapy Center 0.956254 form Cherenkov radiation 0.829553 tumor accumulation 0.82268 atomic number nanoparticles 0.859022 Biology Cancer Center 0.860679 current radiotherapy dosage 0.82716 delivery 0.878526 combination drug delivery 0.856304 current treatment modalities 0.839227 superficial tumor sites 0.867918 innovative nanoparticle packages 0.854373 Gene silencing therapeutics 0.826818 tissue tumor targets 0.869042 electromagnetic radiation 0.829381 nanomaterial-based delivery platforms 0.862296 external electromagnetic radiation 0.823812 tumor 0.913691 tumor microenvironment 0.865684 deep tissue tumors 0.824773	CLICK HERE
17234	National Cancer Institute	Html	en	Adding Immune-based Treatments to Standard Glioblastoma Therapy	This clinical trial is testing standard therapy (surgery, radiation and temozolomide) plus immunotherapy with pembrolizumab with or without a cancer treatment vaccine for patients with newly diagnosed glioblastoma, a common and deadly type of brain tumor.	immune checkpoint inhibitor 0.991382 Dr. Gilbert 0.728039 tumor tissue 0.405841 trial contact information 0.29929 experimental vaccine 0.247456 1-year overall survival 0.300393 NCI’s Cancer 0.233291 Treating Patients 0.208707 little tumor tissue 0.376059 standard therapy plus 0.329661 immune response 0.550076 NCI Clinical Trials 0.330246 chemotherapy drug temozolomide 0.399109 cancer treatment vaccine 0.66133 primary brain tumor 0.428278 Cancer Research 0.215559 clinical trials 0.480839	slow tumor growth 0.416918 partially randomized phase 0.30891 patients 0.251176 Mark R. Gilbert 0.399405 tumor-specific vaccine 0.249165 experimental cancer treatment 0.582716 immune checkpoint inhibitors 0.542772 microscopic tumor 0.266367 newly diagnosed glioblastoma 0.842005 Current standard therapy 0.36143 placebo vaccine 0.253985 immunotherapy drug pembrolizumab 0.351275 median survival time 0.347591 protocol summary 0.359999 radiation therapy 0.342013 standard therapy 0.747186	CLICK HERE